• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Evotec Aktiengesellschaft - Product Pipeline Review - H2 2011 Product Image

Evotec Aktiengesellschaft - Product Pipeline Review - H2 2011

  • Published: November 2011
  • 174 pages
  • Global Markets Direct

Evotec Aktiengesellschaft – Product Pipeline Review – H2 2011

Summary

Global Market Direct’s pharmaceuticals report, “Evotec Aktiengesellschaft - Product Pipeline Review - H2 2011” provides data on the Evotec Aktiengesellschaft’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Evotec Aktiengesellschaft’s corporate website, SEC filings, investor presentations and featured press releases, both from Evotec Aktiengesellschaft and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Evotec Aktiengesellschaft - Brief Evotec Aktiengesellschaft overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Evotec Aktiengesellschaft human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current READ MORE >



List of Tables
List of Figures
Evotec Aktiengesellschaft Snapshot
Evotec Aktiengesellschaft Overview
Key Information
Key Facts
Evotec Aktiengesellschaft – Research and Development Overview
Key Therapeutic Areas
Evotec Aktiengesellschaft – Pipeline Review
Pipeline Products by Stage of Development
Evotec Aktiengesellschaft – Pipeline Products Glance
Evotec Aktiengesellschaft Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Evotec Aktiengesellschaft–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Discovery Products/Combination Treatment Modalities
Evotec Aktiengesellschaft – Drug Profiles
B1 Antagonists
Product Description
Mechanism of Action
R&D Progress
BACE Inhibitors
Product Description
Mechanism of Action
R&D Progress
DG3173
Product Description
Mechanism of Action
R&D Progress
Drug for Anemia
Product Description
Mechanism of Action
R&D Progress
EVT 103
Product Description
Mechanism of Action
R&D Progress
EVT 302
Product Description
Mechanism of Action
R&D Progress
EVT 302 + Nicotine Replacement
Product Description
Mechanism of Action
R&D Progress
EVT 401
Product Description
Mechanism of Action
R&D Progress
EVT501
Product Description
Mechanism of Action
R&D Progress
Insulin Sensitizers
Product Description
Mechanism of Action
R&D Progress
Kv1.3 inhibitors
Product Description
Mechanism of Action
R&D Progress
Orexin 2
Product Description
Mechanism of Action
R&D Progress
P2X3 and P2X2/3 Antagonist
Product Description
Mechanism of Action
R&D Progress
PDE10a inhibitors
Product Description
Mechanism of Action
R&D Progress
Serine Racemase Inhibitors
Product Description
Mechanism of Action
R&D Progress
VR1 Antagonist
Product Description
Mechanism of Action
R&D Progress
Evotec Aktiengesellschaft – Pipeline Analysis
Evotec Aktiengesellschaft – Pipeline Products by Therapeutic Class
Evotec Aktiengesellschaft - Pipeline Products By Target
Evotec Aktiengesellschaft – Pipeline Products by Route of Administration
Evotec Aktiengesellschaft – Pipeline Products by Molecule Type
Evotec Aktiengesellschaft – Recent Pipeline Updates
Evotec Aktiengesellschaft - Dormant Projects
Evotec Aktiengesellschaft - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
EVT 302
EVT 101
EVT-201
ND1251
ND7001
REN-1654
Evotec Aktiengesellschaft – Company Statement
Evotec Aktiengesellschaft – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
May 31, 2005: Renovis Enters In To Collaboration And License Agreement With Pfizer To Develop VR1 Antagonists
Jun 29, 2009: Evotec Announces The Successful Completion Of The First Phase I Study With EVT 401
Jul 28, 2008: ND 7001 Evotec Discontinued
Jun 28, 2005: Neuro3d Initiates Depression Trials With ND7001
Mar 28, 2008: Evotec's EVT 101 Shows To Penetrate The Brain In Man And To Modulate Brain Activity During The Performance Of Cognitive Tasks
Oct 27, 2008: Evotec Reports Phase I Safety Data From Tyramine Interaction Study With EVT 302
Feb 26, 2009: DeveloGen Reports Positive Phase I Clinical Trial Results for DG3173
Aug 25, 2005: Renovis Announces Results Of Phase II Study Of Ren-1654 For The Treatment Of Sciatica
Mar 24, 2004: Evotec Neurosciences Licence NMDA Receptor NR2B Subunit Selective Antagonists From Roche
Mar 22, 2007: Evotec Initiates Its First Phase I Clinical Study With EVT 302
Sep 21, 2006: Evotec Initiates Phase II Clinical Trial With EVT 201 For The Treatment Of Insomnia
Oct 20, 2005: Evotec Reports Positive Results Of Repositioning Clinical Trial On CNS Compound
Nov 18, 2009: Evotec Wins German Government Research Grant
May 18, 2011: Evotec And Roche Announce Phase II Study With NR2B Sub-Type Selective NMDA Antagonist In Treatment-Resistant Depression Voluntarily Terminated
Nov 17, 2006: Evotec Initiates Second Phase II Clinical Trial With Insomnia Drug EVT 201
Oct 16, 2006: Evotec Reports Positive Top-Line Results In Phase II Study With EVT 201 In Elderly Insomniacs With Daytime Sleepiness
Jul 15, 2004: Neuro3d Receives Support From ANVAR For Ongoing Clinical Development of Its Antidepressant ND1251
Nov 14, 2005: Evotec Announces Initiation Of Phase I Clinic Trial With EVT 101
Apr 14, 2008: Evotec Reports Results Of Phase II Proof-Of-Concept Study With EVT 302
Sep 11, 2008: Evotec Reports Start Of Phase II Proof-Of-Concept Quit Rate Study With EVT 302 And Results Of Craving Study
Mar 11, 2010: Evotec Completes Clinical Part Of First Phase I Study Of EVT 103
Mar 11, 2010: Evotec Reports Progress Of EVT 101 In Treatment-Resistant Depression
Nov 09, 2008: Evotec Reports Start of Phase II Proof-of-Concept Quit Rate Study with EVT 302 and Results of Craving Study
Oct 09, 2008: Evotec Announces Phase I Initiation With P2X7 Antagonist
Mar 09, 2009: Evotec And Roche Enters In To Agreement To Develop EVT 101 In Phase II
Oct 08, 2008: DeveloGen Announces Completion Of A Phase I Clinical Trial Of DG3173, A Novel Somatostatin Analogue For The Treatment Of Acromegaly
Sep 08, 2009: Evotec AG Announces Top-Line Results Of Phase Ib Study With EVT 101
Sep 08, 2009: Evotec Starts Phase I With EVT 103, An NR2B-Selective NMDA Receptor Antagonist
Jun 08, 2006: Evotec Announces Positive Phase I/II Clinical Trial Results With Insomnia Treatment EVT 201
an 07, 2008: Evotec Starts Phase II In Smoking Cessation With EVT 302
Jan 07, 2008: Phase I Safety And Tolerability Study With EVT 302 Successfully Completed
Sep 05, 2007: Evotec Reports Details Of The Positive Proof-Of-Concept Phase II Study In Insomnia With EVT 201
May 05, 2008: Evotec Completes Acquisition of Renovis
Jun 04, 2007: Evotec Reports Positive Proof-Of-Concept Top-Line Results With Insomnia Drug Candidate EVT 201
Feb 02, 2010: Evotec And Vifor Pharma Sign Major Cooperation Agreement
Jan 02, 2005: Renovis Announces Completion Of Enrollment In Phase II Trial Of REN-1654 In Post-Herpetic Neuralgia (PHN)
Aug 01, 2008: Evotec Announces Initiation Of Phase I Clinical Trial Of VR1 Antagonist Under Partnership With Pfizer Inc.
Jul 01, 2010: Evotec Initiates Phase II Study Of EVT 101 In Treatment-Resistant Depression Patients
Financial Deals Landscape
Evotec Aktiengesellschaft, Deals Summary
Evotec Aktiengesellschaft, Pharmaceuticals & Healthcare, Deal Details
Asset Transactions
Evotec Acquires Zebrafish Screening Operations From Summit
Evotec Acquires NMR Screening Assets And Intellectual Property From Combinature
Evotec Acquires Rights To JChem From ChemAxon
Venture Financing
Evotec Neurosciences Secures $31 million In Series A Financing
Partnerships
Evotec Enters Into Co-Development Agreement With UCB
Evotec Enters Into Co-Development Agreement With Roche
Evotec Enters Into Drug Discovery Collaboration With UCB
Roche Enters Into Collaboration With Evotec
Evotec Enters Into An Agreement With Active Biotech
Evotec Enters Into Research Collaboration With Harvard University And Howard Hughes Medical Institute
Evotec Enters Into Collaboration With Takeda Cambridge
Evotec Enters Into Collaboration With Merck KGaA
Evotec Enters Into Drug Discovery Agreement With Shionogi
Evotec Enters Into Co-Development Agreement With Genentech
Evotec Extends Research Agreement With Cubist Pharmaceuticals
Evotec Enters Into Co-Development Agreement With Vifor Pharma
Evotec Extends Co-Development Agreement With CHDI
Evotec Extends Research Collaboration With Boehringer Ingelheim
Evotec Enters Into Co-Marketing Agreement With DiscoveRx
Evotec Extends Research Agreement With Ono Pharmaceutical
Evotec Enters Into Research Agreement With Biogen
Evotec Enters Into Research Agreement With Cubist Pharmaceuticals
Evotec Enters Into Co-Development Agreement With Roche
Evotec Enters Into Co-Development Agreement With Novartis
Ono Pharmaceutical Enters Into Drug Discovery Agreement With Evotec
Spermatech Enters Into Co-Development Agreement With Evotec
Evotec Enters Into Co-Development Agreement With InterMune
Evotec Extends Co-Development Agreement With CHDI
Panacos Pharmaceuticals Amends Co-Development Agreement With Evotec
Pfizer Extends Co-Development Agreement With Renovis
Evotec Enters Into Co-Development Agreement With Boehringer Ingelheim
Evotec Enters Into Co-Development Agreement With Interprotein
Evotec Enters Into Co-Development Agreement With Daiichi Pharmaceutical
Evotec Enters Into Co-Development Agreement With CHDI
Evotec Enters Into Co-Development Agreement With DAC
Evotec Enters Into Co-Development Agreement With Roche
Evotec Enters Into Co-Development Agreement With APEIRON Biologics
Evotec And Evotec Neurosciences Amends Co-Development Agreement With Boehringer Ingelheim
Renovis Enters Into Co-Development Agreement With Pfizer
Evotec Extends Co-Development Agreement With Roche
Evotec Enters Into Co-Development Agreement With ALTANA Pharma
Evotec And Evotec Neurosciences Enter Into Research Agreement With Boehringer Ingelheim
Evotec Enters Into Collaboration With Seikagaku
Evotec Enteres Into Drug Discovery Agreement With ActivBiotics
Morphochem Enters Into An Agreement With Evotec
Artemis Pharmaceuticals Enters Into Co-Development Agreement With Evotec Neurosciences
Neuronova Enters Into Co-Development Agreement With Evotec
Evotec Enters Into Drug Discovery Agreement With Guilford Pharmaceuticals
Evotec Enters Into Agreement With Roche
Evotec Expands Co-Development Agreement with Oxford Bioscience
Evotec OAI Enters Into Collaboration Agreement With Toray Industries
Evotec Enters Into Co-Development Agreement With Rib-X Pharmaceuticals
Licensing Agreements
Evotec Enters Into Collaboration Agreement With Hypha Discovery
DIREVO Biotech Enters Into Licensing Agreement With Evotec
Evotec Enters Into License Agreement With A Third Party
Evotec Enters Into Licensing Agreement With MedImmune
Evotec Enters Into Licensing Agreement With Roche
Evotec Neurosciences Enters Into Licensing Agreement With Roche
Equity Offering
Evotec Completes Private Placement Of $23 Million
Renovis Completes Public Offering Of $54 Million
Evotec Completes Public Offering Of $34 Million
Evotec Completes Private Placement Of $9.24 Million
Renovis Completes Initial Public Offering Of $75.9 Million
Asset Transactions
Evotec Sells Chemical Development Business To Aptuit
Acquisition
Evotec To Acquire Remaining 30% Stake In Evotec (India) For $2.3 Million
Evotec Acquires Compound Focus
Evotec Completes Acquisition Of Kinaxo Biotechnologies
Evotec Acquires DeveloGen
Evotec Acquires Majority Stake In Research Support International From DIL
Bayer HealthCare Acquires DIREVO Biotech
Evotec Acquires Renovis
Evotec Acquires Neuro3d
PerkinElmer Acquires Evotec Technologies
Evotec Acquires Minority Stakes In ProPharma
Evotec Acquires Evotec Neurosciences
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Evotec Aktiengesellschaft – Pipeline by Therapy Area and Indication, H2 2011
Evotec Aktiengesellschaft – Pipeline by Stage of Development, H2 2011
Evotec Aktiengesellschaft - Phase II, H2 2011
Evotec Aktiengesellschaft - Phase I, H2 2011
Evotec Aktiengesellschaft - Pipeline By Therapeutic Class, H2 2011
Evotec Aktiengesellschaft - Pipeline By Target, H2 2011
Evotec Aktiengesellschaft – Pipeline By Route of Administration, H2 2011
Evotec Aktiengesellschaft – Pipeline By Molecule Type, H2 2011
Evotec Aktiengesellschaft – Recent Pipeline Updates, H2 2011
Evotec Aktiengesellschaft - Dormant Developmental Projects, 2010
Evotec Aktiengesellschaft - Discontinued Pipeline Products, 2010
Evotec Aktiengesellschaft, Other Locations
Evotec Aktiengesellschaft, Subsidiaries
Evotec Aktiengesellschaft, Deals Summary
Evotec Acquires Zebrafish Screening Operations From Summit
Evotec Acquires NMR Screening Assets And Intellectual Property From Combinature
Evotec Acquires Rights To JChem From ChemAxon
Evotec Neurosciences Secures $31 million In Series A Financing
Evotec Enters Into Co-Development Agreement With UCB
Evotec Enters Into Co-Development Agreement With Roche
Evotec Enters Into Drug Discovery Collaboration With UCB
Roche Enters Into Collaboration With Evotec
Evotec Enters Into An Agreement With Active Biotech
Evotec Enters Into Research Collaboration With Harvard University And Howard Hughes Medical Institute
Evotec Enters Into Collaboration With Takeda Cambridge
Evotec Enters Into Collaboration With Merck KGaA
Evotec Enters Into Drug Discovery Agreement With Shionogi
Evotec Enters Into Co-Development Agreement With Genentech
Evotec Extends Research Agreement With Cubist Pharmaceuticals
Evotec Enters Into Co-Development Agreement With Vifor Pharma
Evotec Extends Co-Development Agreement With CHDI
Evotec Extends Research Collaboration With Boehringer Ingelheim
Evotec Enters Into Co-Marketing Agreement With DiscoveRx
Evotec Extends Research Agreement With Ono Pharmaceutical
Evotec Enters Into Research Agreement With Biogen
Evotec Enters Into Research Agreement With Cubist Pharmaceuticals
Evotec Enters Into Co-Development Agreement With Roche
Evotec Enters Into Co-Development Agreement With Novartis
Ono Pharmaceutical Enters Into Drug Discovery Agreement With Evotec
Spermatech Enters Into Co-Development Agreement With Evotec
Evotec Enters Into Co-Development Agreement With InterMune
Evotec Extends Co-Development Agreement With CHDI
Panacos Pharmaceuticals Amends Co-Development Agreement With Evotec
Pfizer Extends Co-Development Agreement With Renovis
Evotec Enters Into Co-Development Agreement With Boehringer Ingelheim
Evotec Enters Into Co-Development Agreement With Interprotein
Evotec Enters Into Co-Development Agreement With Daiichi Pharmaceutical
Evotec Enters Into Co-Development Agreement With CHDI
Evotec Enters Into Co-Development Agreement With DAC
Evotec Enters Into Co-Development Agreement With Roche
Evotec Enters Into Co-Development Agreement With APEIRON Biologics
Evotec And Evotec Neurosciences Amends Co-Development Agreement With Boehringer Ingelheim
Renovis Enters Into Co-Development Agreement With Pfizer
Evotec Extends Co-Development Agreement With Roche
Evotec Enters Into Co-Development Agreement With ALTANA Pharma
Evotec And Evotec Neurosciences Enter Into Research Agreement With Boehringer Ingelheim
Evotec Enters Into Collaboration With Seikagaku
Evotec Enteres Into Drug Discovery Agreement With ActivBiotics
Morphochem Enters Into An Agreement With Evotec
Artemis Pharmaceuticals Enters Into Co-Development Agreement With Evotec Neurosciences
Neuronova Enters Into Co-Development Agreement With Evotec
Evotec Enters Into Drug Discovery Agreement With Guilford Pharmaceuticals
Evotec Enters Into Agreement With Roche
Evotec Expands Co-Development Agreement with Oxford Bioscience
Evotec OAI Enters Into Collaboration Agreement With Toray Industries
Evotec Enters Into Co-Development Agreement With Rib-X Pharmaceuticals
Evotec Enters Into Collaboration Agreement With Hypha Discovery
DIREVO Biotech Enters Into Licensing Agreement With Evotec
Evotec Enters Into License Agreement With A Third Party
Evotec Enters Into Licensing Agreement With MedImmune
Evotec Enters Into Licensing Agreement With Roche
Evotec Neurosciences Enters Into Licensing Agreement With Roche
Evotec Completes Private Placement Of $23 Million
Renovis Completes Public Offering Of $54 Million
Evotec Completes Public Offering Of $34 Million
Evotec Completes Private Placement Of $9.24 Million
Renovis Completes Initial Public Offering Of $75.9 Million
Evotec Sells Chemical Development Business To Aptuit
Evotec To Acquire Remaining 30% Stake In Evotec (India) For $2.3 Million
Evotec Acquires Compound Focus
Evotec Completes Acquisition Of Kinaxo Biotechnologies
Evotec Acquires DeveloGen
Evotec Acquires Majority Stake In Research Support International From DIL
Bayer HealthCare Acquires DIREVO Biotech
Evotec Acquires Renovis
Evotec Acquires Neuro3d
PerkinElmer Acquires Evotec Technologies
Evotec Acquires Minority Stakes In ProPharma
Evotec Acquires Evotec Neurosciences

List of Figures
Evotec Aktiengesellschaft – Pipeline by Therapy Area and Indication, H2 2011
Evotec Aktiengesellschaft – Pipeline by Stage of Development, H2 2011
Evotec Aktiengesellschaft – Pipeline By Therapeutic Class, H2 2011
Evotec Aktiengesellschaft - Pipeline By Target, H2 2011
Evotec Aktiengesellschaft – Pipeline By Route of Administration, H2 2011

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos